Sarepta Therapeutics (SRPT) Falls As Patent Settlement Tests The Undervalued Narrative

Sarepta Therapeutics (SRPT) is back in focus after a sector-wide biotech selloff pushed the share price down 7.1% to $19.33, shortly after a major patent litigation settlement.

Over the past week Sarepta Therapeutics has seen the share price retreat, with a 7-day share price return of down 11.03% and a 1-day move of down 2.96% to US$18.39. However, the 90-day share price return of 9.14% and 1-year total shareholder return of 3.78% point to fragile momentum rebuilding after much deeper 3 and 5-year total shareholder return declines.

Scan beyond Sarepta Therapeutics and explore how other beaten-up biotech plays with stronger balance sheets are shaping up in our hand-picked list of solid balance sheet and fundamentals (24 results) today.

The share price slide and litigation overhang now leave Sarepta Therapeutics looking very different to where it traded just months ago. Does that present a more attractive entry point today, or does it argue for waiting until the valuation resets further?

Most Popular Narrative: 15% Undervalued

Against Sarepta Therapeutics' last close at $18.39, the most followed valuation narrative points to a fair value of about $21.65. This frames the recent pullback as a sizeable disconnect that depends on how the pipeline develops.

The analysts have a consensus price target of $21.65 for Sarepta Therapeutics based on their expectations of its future earnings growth, profit margins and other risk factors. In order for you to agree with the analysts, you'd need to believe that by 2029, revenues will be $1.4 billion, earnings will come to $87.3 million, and it would be trading on a PE ratio of 39.8x, assuming you use a discount rate of 7.8%.

See why 40 investors see Sarepta Therapeutics as 15% undervalued.

Result: Fair Value of $21.65 (UNDERVALUED)

Still, the narrative around Sarepta Therapeutics can change quickly if ELEVIDYS safety concerns deepen or if administrative bottlenecks continue to delay gene therapy treatments and related revenue.

Find out about the key risks to this Sarepta Therapeutics narrative.

Next Steps

Mixed about Sarepta Therapeutics after all this, yet feeling the clock is ticking on forming a clear view. To evaluate both potential upside and downside in one place, see the 2 key rewards and 1 important warning sign.

Looking for more investment ideas beyond Sarepta Therapeutics?

If Sarepta Therapeutics has sharpened your thinking, use that momentum to evaluate a few more setups that might fit your style and risk tolerance.

• Target reliable income and resilience by reviewing companies in the 8 dividend fortresses that may suit a steady cash flow focus.
• Hunt for quality at a reasonable price by scanning the 30 high quality undervalued stocks that fit strict fundamental filters.
• Spot tomorrow's potential leaders early by checking out the 16 high quality undiscovered gems before they appear on everyone else's radar.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com